Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
Clostridium difficile (C. difficile) infection (CDI) is the main cause of nosocomial antibiotic-associated colitis and increased incidence of community-associated diarrhea in industrialized countries. At present, the primary treatment of CDI is antibiotic administration, which is effective but often...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4919053?pdf=render |
| _version_ | 1811295085665452032 |
|---|---|
| author | Hongyu Qiu Robyn Cassan Darrell Johnstone Xiaobing Han Antony George Joyee Monica McQuoid Andrea Masi John Merluza Bryce Hrehorak Ross Reid Kieron Kennedy Bonnie Tighe Carla Rak Melanie Leonhardt Brian Dupas Laura Saward Jody D Berry Cory L Nykiforuk |
| author_facet | Hongyu Qiu Robyn Cassan Darrell Johnstone Xiaobing Han Antony George Joyee Monica McQuoid Andrea Masi John Merluza Bryce Hrehorak Ross Reid Kieron Kennedy Bonnie Tighe Carla Rak Melanie Leonhardt Brian Dupas Laura Saward Jody D Berry Cory L Nykiforuk |
| author_sort | Hongyu Qiu |
| collection | DOAJ |
| description | Clostridium difficile (C. difficile) infection (CDI) is the main cause of nosocomial antibiotic-associated colitis and increased incidence of community-associated diarrhea in industrialized countries. At present, the primary treatment of CDI is antibiotic administration, which is effective but often associated with recurrence, especially in the elderly. Pathogenic strains produce enterotoxin, toxin A (TcdA), and cytotoxin, toxin B (TcdB), which are necessary for C. difficile induced diarrhea and gut pathological changes. Administration of anti-toxin antibodies provides an alternative approach to treat CDI, and has shown promising results in preclinical and clinical studies. In the current study, several humanized anti-TcdA and anti-TcdB monoclonal antibodies were generated and their protective potency was characterized in a hamster infection model. The humanized anti-TcdA (CANmAbA4) and anti-TcdB (CANmAbB4 and CANmAbB1) antibodies showed broad spectrum in vitro neutralization of toxins from clinical strains and neutralization in a mouse toxin challenge model. Moreover, co-administration of humanized antibodies (CANmAbA4 and CANmAbB4 cocktail) provided a high level of protection in a dose dependent manner (85% versus 57% survival at day 22 for 50 mg/kg and 20 mg/kg doses, respectively) in a hamster gastrointestinal infection (GI) model. This study describes the protective effects conferred by novel neutralizing anti-toxin monoclonal antibodies against C. difficile toxins and their potential as therapeutic agents in treating CDI. |
| first_indexed | 2024-04-13T05:28:07Z |
| format | Article |
| id | doaj.art-055bd6e30c8944148ae1b35087fb9f61 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T05:28:07Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-055bd6e30c8944148ae1b35087fb9f612022-12-22T03:00:32ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01116e015797010.1371/journal.pone.0157970Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.Hongyu QiuRobyn CassanDarrell JohnstoneXiaobing HanAntony George JoyeeMonica McQuoidAndrea MasiJohn MerluzaBryce HrehorakRoss ReidKieron KennedyBonnie TigheCarla RakMelanie LeonhardtBrian DupasLaura SawardJody D BerryCory L NykiforukClostridium difficile (C. difficile) infection (CDI) is the main cause of nosocomial antibiotic-associated colitis and increased incidence of community-associated diarrhea in industrialized countries. At present, the primary treatment of CDI is antibiotic administration, which is effective but often associated with recurrence, especially in the elderly. Pathogenic strains produce enterotoxin, toxin A (TcdA), and cytotoxin, toxin B (TcdB), which are necessary for C. difficile induced diarrhea and gut pathological changes. Administration of anti-toxin antibodies provides an alternative approach to treat CDI, and has shown promising results in preclinical and clinical studies. In the current study, several humanized anti-TcdA and anti-TcdB monoclonal antibodies were generated and their protective potency was characterized in a hamster infection model. The humanized anti-TcdA (CANmAbA4) and anti-TcdB (CANmAbB4 and CANmAbB1) antibodies showed broad spectrum in vitro neutralization of toxins from clinical strains and neutralization in a mouse toxin challenge model. Moreover, co-administration of humanized antibodies (CANmAbA4 and CANmAbB4 cocktail) provided a high level of protection in a dose dependent manner (85% versus 57% survival at day 22 for 50 mg/kg and 20 mg/kg doses, respectively) in a hamster gastrointestinal infection (GI) model. This study describes the protective effects conferred by novel neutralizing anti-toxin monoclonal antibodies against C. difficile toxins and their potential as therapeutic agents in treating CDI.http://europepmc.org/articles/PMC4919053?pdf=render |
| spellingShingle | Hongyu Qiu Robyn Cassan Darrell Johnstone Xiaobing Han Antony George Joyee Monica McQuoid Andrea Masi John Merluza Bryce Hrehorak Ross Reid Kieron Kennedy Bonnie Tighe Carla Rak Melanie Leonhardt Brian Dupas Laura Saward Jody D Berry Cory L Nykiforuk Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model. PLoS ONE |
| title | Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model. |
| title_full | Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model. |
| title_fullStr | Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model. |
| title_full_unstemmed | Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model. |
| title_short | Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model. |
| title_sort | novel clostridium difficile anti toxin tcda and tcdb humanized monoclonal antibodies demonstrate in vitro neutralization across a broad spectrum of clinical strains and in vivo potency in a hamster spore challenge model |
| url | http://europepmc.org/articles/PMC4919053?pdf=render |
| work_keys_str_mv | AT hongyuqiu novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel AT robyncassan novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel AT darrelljohnstone novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel AT xiaobinghan novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel AT antonygeorgejoyee novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel AT monicamcquoid novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel AT andreamasi novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel AT johnmerluza novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel AT brycehrehorak novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel AT rossreid novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel AT kieronkennedy novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel AT bonnietighe novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel AT carlarak novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel AT melanieleonhardt novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel AT briandupas novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel AT laurasaward novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel AT jodydberry novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel AT corylnykiforuk novelclostridiumdifficileantitoxintcdaandtcdbhumanizedmonoclonalantibodiesdemonstrateinvitroneutralizationacrossabroadspectrumofclinicalstrainsandinvivopotencyinahamstersporechallengemodel |